Pages that link to "Q43260679"
Jump to navigation
Jump to search
The following pages link to Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice (Q43260679):
Displaying 15 items.
- Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer (Q26863418) (← links)
- Control of the immune response by pro-angiogenic factors (Q27004733) (← links)
- Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. (Q34473451) (← links)
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy (Q35028389) (← links)
- Tissue resident regulatory T cells: novel therapeutic targets for human disease (Q36085091) (← links)
- Update on vaccine development for renal cell cancer (Q36989720) (← links)
- Advances in Cellular Therapy for the Treatment of Thyroid Cancer (Q37776660) (← links)
- Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy (Q37830361) (← links)
- Modulation of immunity by antiangiogenic molecules in cancer (Q38074154) (← links)
- Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo (Q38712735) (← links)
- Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes (Q38920881) (← links)
- Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells (Q39581139) (← links)
- A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs (Q42344612) (← links)
- Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response (Q48030659) (← links)
- Aging Mouse Models Reveal Complex Tumor-Microenvironment Interactions in Cancer Progression. (Q52322881) (← links)